CDD-0098
CDD-0098 is an investigational drug currently under development for the treatment of neurodegenerative disorders. It is being studied for its potential efficacy in conditions such as Alzheimer's disease and Parkinson's disease. CDD-0098 is a small molecule that acts as a selective inhibitor of a specific enzyme involved in the pathogenesis of these diseases.
Mechanism of Action[edit | edit source]
CDD-0098 functions by inhibiting the activity of the enzyme beta-secretase, which is involved in the production of beta-amyloid peptides. These peptides aggregate to form plaques, a hallmark of Alzheimer's disease pathology. By reducing the formation of beta-amyloid, CDD-0098 aims to slow or halt the progression of neurodegeneration.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of CDD-0098 has been characterized in preclinical studies. It exhibits good oral bioavailability and is able to cross the blood-brain barrier, which is essential for its action in the central nervous system. The drug is primarily metabolized in the liver and has a half-life that supports once-daily dosing.
Clinical Trials[edit | edit source]
CDD-0098 is currently in Phase II clinical trials. Initial results have shown promise in reducing cognitive decline in patients with mild to moderate Alzheimer's disease. The trials are also assessing the safety and tolerability of the drug, with a focus on monitoring for any adverse effects related to its mechanism of action.
Potential Side Effects[edit | edit source]
As with any investigational drug, CDD-0098 may have side effects. Commonly reported adverse effects in clinical trials include headache, nausea, and dizziness. Long-term safety data are still being collected.
Research and Development[edit | edit source]
The development of CDD-0098 is being led by a consortium of academic institutions and pharmaceutical companies. The research is funded by grants from various governmental and non-governmental organizations dedicated to advancing treatments for neurodegenerative diseases.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
